Colorectal Cancer
Advertisement
A study assessed whether the addition of anti-VEGF agent to first-line treatment impacted outcomes in metastatic CRC.
Maintenance with cetuximab monotherapy appeared to improve PFS and OS in patients with metastatic colorectal cancer.
A study assessed the efficacy of a treatment combination in the second-line treatment of metastatic colorectal cancer.
The combination of pembrolizumab and lenvatinib did not improve survival in metastatic CRC.
A systematic review reported that immune checkpoint inhibitor therapy shows promising results in metastatic CRC.
The FRESCO-2 study showed that fruquintinib resulted in an overall survival benefit in metastatic colorectal cancer.
Dr. Eng discusses the phase 3 FRESCO-2 study and how fruquintinib fits in with current treatments for advanced CRC.
The rate of colorectal cancer (CRC) screenings decreased by more than 20% during the COVID-19 pandemic.
The Oncology Brothers speak with Cathy Eng, MD, about treatment of metastatic colorectal cancer with fruquintinib.
Treatment with avelumab improved progression-free survival in patients with mCRC.
Patients diagnosed with colorectal liver metastases in expert hospitals receive better treatment.
A novel classification system for molecular subtypes of colorectal liver metastasis was found to be linked with prognosis.
A new study has identified 7 risk factors for early onset of colorectal cancer in male patients.
Fruquintinib combined with the anti-programmed death-1 antibody toripalimab is effective in treating advanced colon cancer.
Racial disparities in mortality associated with CRC may be related to lower availability of primary care physicians.
Systemic chemotherapy combined with radiofrequency ablation appears safe and effective in patients with colorectal cancer.
Fruquintinib meaningfully improved overall survival in patients with refractory metastatic colorectal cancer versus placebo.
Systemic chemotherapy did not show any benefit in patients with inoperable low-grade mucinous appendiceal adenocarcinoma.
Researchers have identified how common genetic factors can be used to discern which individuals are at high risk for CRC.
Extending colorectal cancer screening to older populations using stool testing results in more life years gained.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.